Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz, Linda M. Henricks, Steven M. Offer et al. · Clinical Pharmacology & Therapeutics · 2017
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase ( DPYD ) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5‐fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost‐effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline‐for‐fluoropyrimidines‐and‐dpyd/ ).
Cited by 694 works. doi:10.1002/cpt.911 Open-access PDF
Authors
- Ursula Amstutz
- Linda M. Henricks
- Steven M. Offer
- Julia M. Barbarino
- Jan H.M. Schellens
- Jesse Joachim Swen
- Teri E. Klein
- Howard L. McLeod
- Kelly E. Caudle
- Robert B. Diasio
- Matthias Georg Schwab
References
- Global cancer statistics
- Global cancer statistics, 2012
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
- Clinical Pharmacology of 5-Fluorouracil
- Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
- Pharmacogenetics: From Bench to Byte— An Update of Guidelines
- Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
- Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
- Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data